← All trials
NCT05169554
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Dec 27, 2021
- Last posted
- Dec 27, 2021
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)Lead sponsor
- Fondation Raoul FollereauCollaborator
- Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)Study director
- Universidad Carlos III MadridCollaborator
- University of ZaragozaCollaborator
- Université d'Abomey-CalaviCollaborator
- GlaxoSmithKlineCollaborator
- Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.